Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Cardiogenesis Corp (CGCP)
|
Add to portfolio |
|
|
|
| Price: |
$0.46
| | Metrics |
| OS: |
46.7
|
M
| |
-101
|
% ROE
|
| Market cap: |
$21.5
|
M
| |
-289
|
% ROIC
|
|
Net cash:
|
$1.09
|
M
| |
$0.02
|
per share
|
|
EV:
|
$20.4
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($1.6)
|
M
| |
|
|
|
EBIT
|
($1.9)
|
M
| |
|
|
| EPS |
($15.57)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-05 | Dec-31-04 | Dec-31-03 | Dec-31-02 |
| Revenues | 11.3 | 10.4 | 12.2 | 12.1 | 16.3 | 15.5 | 13.5 | 13.0 |
| Revenue growth | 9.0% | -14.8% | 0.8% | | 5.7% | 14.3% | 3.6% | -7.8% |
| Cost of goods sold | 1.8 | 1.8 | 2.2 | 2.9 | 3.0 | 2.2 | 2.3 | 2.9 |
| Gross profit | 9.5 | 8.5 | 9.9 | 9.1 | 13.3 | 13.3 | 11.2 | 10.1 |
| Gross margin | 83.7% | 82.5% | 81.6% | 75.5% | 81.7% | 85.8% | 83.0% | 77.5% |
| Selling, general and administrative | | | | | 14.1 | 11.3 | 9.6 | 12.3 |
| Sales and marketing | 6.2 | 5.6 | 6.5 | 4.4 | | | | |
| Research and development | 1.5 | 1.3 | 0.9 | 0.7 | 1.7 | 1.4 | 1.9 | 0.7 |
| General and administrative | 3.3 | 2.8 | 2.8 | 3.1 | | | | |
| EBIT | -1.4 | -1.1 | -0.3 | 0.9 | -2.5 | 0.5 | -0.3 | -5.1 |
| EBIT margin | -12.7% | -10.8% | -2.6% | 7.1% | -15.2% | 3.2% | -2.3% | -39.3% |
| Pre-tax income | -1.3 | -1.2 | -0.3 | 0.6 | -1.9 | -1.3 | -0.3 | -0.5 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | | | 2.2% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -1.3 | -1.2 | -0.3 | 0.6 | -1.9 | -1.3 | -0.3 | -0.5 |
| Net margin | -11.4% | -11.9% | -2.6% | 4.8% | -11.4% | -8.5% | -2.6% | -4.1% |
| |
| Diluted EPS | ($28.01) | ($27.11) | ($0.01) | $0.01 | ($0.04) | ($0.03) | ($0.01) | ($0.01) |
| Shares outstanding (diluted) | 0.0 | 0.0 | 45.3 | 45.3 | 43.4 | 41.2 | 37.3 | 36.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|